Bristol Myers Squibb (BMS) will partner with Hengrui Pharma to co-develop 13 early-stage programs in oncology, hematology, and immunology, through a collaboration that could generate more than $15.2 ...

Bristol Myers Squibb (BMS) has agreed to acquire its longtime cell therapy partner 2seventy bio in a deal valued at $286m. Announced after markets closed on 10 March, the $5-per-share offer represents ...

Bristol Myers Squibb has forged close ties with China's Hengrui Pharma, partnering across 13 programmes in oncology, ...

Bristol Myers Squibb has formed a broad partnership with Hengrui Pharma, paying $600 million upfront to advance 13 early-stage programs from across the two companies’ pipelines. The deal could be ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration ...

The two companies will trade the greater Chinese and US rights to certain programmes under their jurisdiction, while working in tandem to progress these assets.

Bristol Myers Squibb said in its fourth-quarter results update this morning that it will double down on an ongoing cost-cutting programme announced last year. The company still intends to slash $1.5 ...

After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers Squibb’s Cobenfy appear set to arrive later this year.

China's Hengrui and US-based Bristol Myers Squibb (BMS) sign a $15.2 billion collaboration deal. A major step for China's ...

Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos ...

Regionalized early development affects clinical supply, analytical transfer, comparability strategies, and regulatory ...